Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability.

TL;DR: It is concluded that patients expressing CYP3A5 need more tacrolimus to reach target concentrations and have a lower tac rolimus exposure shortly after transplantation, but this delay in reaching target concentrations did not result in an increased incidence of early BPAR and therefore, genotyping for CYP 3A5 is unlikely to improve short-term transplantation outcome.

TL;DR: Future prospects point in the direction of individualization of antiretroviral therapy through insights from host genetics, according to a comprehensive review of the published literature.

TL;DR: Functional data demonstrate that nonsynonymous polymorphisms in ABCB1 may selectively alter P-gp transport and drug-drug interactions in a substrate- and inhibitor-dependent manner.

TL;DR: A pharmacogenomics education program is developed to disseminate evidence-based pharmacogenomic information and provide a resource for health professionals, including pharmacists.

TL;DR: A significant correlation of a polymorphism in exon 26 (C3435T) of MDR-1 with expression levels and function is observed and this polymorphism is expected to affect the absorption and tissue concentrations of numerous other substrates of M DR-1.

TL;DR: Allelic variation in MDR1 is more common than previously recognized and involves multiple SNPs whose allelic frequencies vary between populations, and some of these SNPs are associated with altered P‐glycoprotein function.

TL;DR: Some synonymous mutations in the human DRD2 have functional effects and suggest a novel genetic mechanism, calling into question some assumptions made about synonymous variation in molecular population genetics and gene-mapping studies of diseases with complex inheritance, and indicate that synonymous variation can have effects of potential pathophysiological and pharmacogenetic importance.

TL;DR: SNPs in MDR1 in relation to population frequencies, drug levels, and phenotypes are outlined and issues relating to M DR1 haplotypes, environmental factors, and study design, as potential confounding factors of the observed MDR 1 polymorphism effect in vivo, are discussed.